

April 2023

## There's A New TTCF Chair In Town

*Richelle Holnick, OTT*

Meet Sidra Ahsan, the new Technology Transfer Community Forum (TTCF) Chair! You might be familiar with Sidra as she already has a few meetings under her belt as chair, or from her work at the National Cancer Institute Technology Transfer Center (NCI TTC), where she has been since 2016.

Sidra received her Ph.D. in Cancer Biology from Wayne State University and Karmanos Cancer Institute in Detroit, MI. Following graduation, she considered going to law school to pursue a career in patent law but felt too academically burnt out. Instead, she took a position as a product manager at a biotech startup, Advaita Bioinformatics in Ann Arbor, MI, to learn the business side of science. Here Sidra managed the lead product, a multi-omics pathway analysis platform. This position gave her a wide variety of experience as she was heavily involved in marketing, product development, client relations, and sales.



Sidra Ahsan

When Sidra attended an industry conference during this period, she was already starting to miss the academic research environment. At this conference she learned about the field of technology transfer and realized that it was perfect for her as it combined all her interests: science, law, and business. She also met an NCI TTC Fellow alum who introduced her to the TTC fellowship program. She had interned as a Summer CRTA at the Curtis Harris lab in 2010 and knew that she wanted to come back and work at NIH/NCI in some capacity. So, she applied to the fellowship program, got accepted, and the rest as they say, is history!

When asked what her favorite part of working at NIH is, Sidra said that “NIH is a unique community of experts with a similar goal of promoting public health. In addition, the greatest part about working here is that I continue to learn something new whether it is about a new discovery, invention, policy, etc.”

As I mentioned, Sidra is the new TTCF Chair. She was interested in taking on this position because it provides a unique opportunity to step outside of her daily work, interact with the larger community, and get involved in the ‘big picture’ of tech transfer. As the TTCF Chair, she has been able to learn about different types of tech transfer activities across the ICs, FDA, and CDC, and work with senior leadership at these ICs and agencies, which is a relatively rare opportunity for a non-Technology Development Coordinator.


# In This Issue

There's a New TTCF Chair in Town.....	1
ETT is Burning In .....	3
The History, and Future, of the Technology Transfer Collection.....	7
Technology Transfer University (TTU) – Spring 2023 .....	9
AUTM Annual Meeting .....	11
iEdison Platform Receives FLC Award.....	13
OSA at AUTM .....	14
My FLC Experience.....	15
NIAID Wins USPTO Patents for Humanity COVID-19 Award .....	16
Abstract Creation Progress Bar .....	16
Now Showing: ETT Training Videos.....	17
Patent Legal Services Reminder .....	17
Comings and Goings .....	18



As Chair, Sidra is interested in supporting the new and relatively junior members of our community. She wants to provide a more streamlined interactive platform via TTCF and improve communication and sharing of information. She knows that many folks are

unaware of the various tech transfer groups and working group opportunities available outside of their respective offices. Sidra and Janette Lebron, the TTCF Vice Chair, are working on different ways of improving the sharing of information. Sidra also has some interesting topics and speakers lined up and wants to hear from both the junior and senior members of the community on topics and speakers of interest. She boasts that her virtual door is always open!



Sidra's new movie

Outside of work, you can find Sidra chasing after her two toddlers, doing yoga, traveling, reading, and hanging out with friends and family. You might also be able to spot her in a movie titled “To Live and Die and Live” which recently premiered at the Sundance Film Festival! It is an independent drama film, so there is no information on when and if it will make it to theaters or streaming services, but if you end up watching it, you may be able to catch her acting as an extra in a funeral scene!

New TTCF Chair

# ETT is Burning In

Terry Goodell, Sapiient

The Enterprise Technology Transfer (ETT) system launched to the full community on December 20, 2022 and has been running full steam ahead since then. Users were anxious to get their hands on this new system – of the 200+ active ETT users, 118 of them logged in during the first week. The effort it took to get us to this point was enormous. The ETT team combined nine databases which contained more than 13 million rows of data. They reviewed, analyzed, and mapped 7,857 fields in 591 tables. We have also created over 80,000 lines of database code in order to combine the data logically. To support the development and migration efforts, the team built and maintained seven environments including SANDBOX, PREVIEW, DEV1, DEV2, QA, STAGE and PRODUCTION. We have used these different environments for prototyping, development, testing, demonstrations, training and, of course, going live with ETT. To simplify the abstract loading process and link to the NIH Tech

Transfer website, an Application Programming Interface (API) was built. Further work is broken out in the following graphics including pre-launch and Authority to Operate (ATO):

## PRE-LAUNCH WORK

### BACKLOG ITEMS

Over 700 backlog items were logged, analyzed, prioritized

### SENTINEL RULES AND TRIGGERS

Within the 700 backlog items, 30 sentinel rules and 75 triggers were implemented

### ENHANCEMENTS

Over 330 enhancements were completed

### REPORTS AND FORMS

Over 100 custom reports and forms were developed and deployed



## ATO BY THE NUMBERS

2

### YEARS

It took 2 years to compile the ATO package and prepare it for submission

24

### POLICY & PROCESS DOCUMENTS

The policy and process documents provided in the ATO package show how OTT plans to safeguard all data in the ETT system.

100

### ARTIFACTS

These 100 artifacts are made up of 100s of pages of documentation about the system.

1100

### SECURITY CONTROLS

Security controls ensure the security and safety of the system.



We could not discuss ETT without also discussing the Law Firm Portal (LFP). The new LFP was built to be more stable and able to handle a larger concurrent user base. It will give the law firms more visibility into the status of their TORFQs and give them the ability to enter itemized invoices. It will be an elevated platform which provides end-users with a quicker



## LAW FIRM PORTAL

### 3,000+ QUOTES

The LFP was built to handle moving 3,000+ quotes between itself and ETT per year.

### 6,000+ DOCUMENTS

The LFP was built to move 6,000+ documents between itself and ETT per year.

### 3,000+ INVOICES

The LFP was built to process 3,000+ invoices per year.

### 10,000+ CORRESPONDENCE

The LFP was built to move 10,000+ pieces of correspondence between itself and ETT.

performance response time and robust searching capabilities. It will also allow for the uploading of multiple (5) documents at one time and exporting Excel reports.

## Enterprise Involvement


Involvement from the community on this project has been excellent. Users have helped to identify needed changes or enhancements and test those changes. During user Acceptance Testing alone, 127 community testers, working with the ETT team, used 454 Use Cases and 185 Test Cases to test ETT. Many of these early adopters were also quick to email ETT support for help or further training as they learned and tested the system. In the past year, we have received over 4300 support requests. Learning a new system can be intimidating, so the ETT team has provided a variety of avenues for training and receiving assistance.

Between December 12th (ETT's soft-launch) and the end of March 2023, the ETT team has provided:


## TRAINING



The ETT team has been handling a large influx of support tickets – over 1,000 in just over three months! Of those 1,000, less than 100 are currently open.



All other ETT support tickets have been resolved or are a change request that was moved to the backlog. The backlog has seen 152 change requests come in since go-live, with 107 of them being completed already. To accomplish this, there have been twelve deployments since go-live.



While we have been telling everyone about the benefits ETT will bring, we are so excited that the community is now able to access ETT and use it as the system of record so that they can feel the benefits themselves! We spoke with some community members to hear how ETT has improved their work thus far:

ETT is Burning In



There are many powerful new features in our new ETT platform and two of note are certainly the editable grid view functionality and Excel export feature. In OTT we face a high daily volume of wide ranging and time sensitive administrative tasks. The ability to quickly create, save, upload and share with team members a variety of customized grid views and filter preferences for targeted administrative tasks coupled with the seamless export of the data to Excel files, are welcome upgrades to TechTracS.



- Kevin J. Doran  
Royalties Administrator, Office of Technology Transfer



The immediate benefit to NIH became evident as early as February 2023 when the NIH leveraged the newly launched enterprise technology transfer system (ETT) to zero-in on the ICs implicated in a time-sensitive congressional enquiry. A single search in the ETT enabled the rapid identification of records relevant to the request, obviating the need to query ICs and wait for responses to trickle in from individual IC databases. The level of transparency and accessibility to all of NIH's technology transfer records afforded by a single system is unprecedented and a game-changer for how we view, use and leverage NIH's vast store of valuable technology transfer information.



- Surekha Vathyam, Ph.D.  
Deputy Director, Technology Transfer and Intellectual Property Office, NIAID

## Next Steps

So where do we go from here? As the title of this article alludes to, ETT is currently in what is known as a 'burn in' phase. Users are adjusting to the system and the ETT team is helping to work out any kinks in the system or address any data issues. The integrity of the data in the system is of the utmost priority to the ETT team. They did extensive work preparing and migrating the data into ETT; however, the data de-duplication work is an ongoing effort. ETT's burn in phase will continue until steady state is declared. Once we reach this point, the ETT Support email helpdesk will be transitioned to ServiceNow to allow for more automation and quicker categorization of each user's ticket. More information will be provided before the switch occurs.

We know that switching to a new system is not easy, but we appreciate the community's patience as we all adjust to this new world. As always, if you have any questions or concerns, please reach out to [ETT\\_Support@mail.nih.gov](mailto:ETT_Support@mail.nih.gov).

# History (and Future) of the Tech Transfer Collection

Devon Valera, ONHM

Early this year, the Office of NIH History and Stetten Museum (ONHM) had the honor of accepting a collection from OTT of commercial products derived from collaborations between NIH intramural researchers and industry. After a thorough inventory, the first step in the accession process, we now number this diverse collection at 58 objects, including at-home test kits, vaccines, and even bird seed. ONHM hopes to grow this technology transfer collection in collaboration with OTT as more products are brought to market in the future.

Immediately upon accepting the collection, ONHM was contacted by the Deutsches Hygiene-Museum in Dresden, Germany. The museum was planning an exhibit entitled *Of Genes and Human Beings* (German: Von Genen und Menschen), which opened on February 11, 2023, and will be on display until September 10, 2023. The exhibit explores advances in genetic research and medical technology following the sequencing of the human genome. The Deutsches Hygiene-Museum was interested in displaying Myriad's BRCAAnalysis test kit, which was developed using NIEHS research that isolated the BRCA2 gene. Hereditary mutations on BRCA1 and BRCA2 genes are linked with an elevated risk of breast cancer. By testing these genetic markers, the test kit empowered individuals to make decisions about preventative treatment for breast cancer.



Squirrel Free Seed Saver was created from NCI research on capsaicin.



Pamphlet for Deutsches Hygiene-Museum exhibit Von Genen und Menschen (English: *Of Genes and Human Beings*)

Objects from the technology transfer collection will inform two upcoming ONHM exhibits slated for installation this year on the Bethesda campus. HIV test kits developed using research from the National Cancer Institute, the National Institute for Allergy and Infectious Diseases, and the Department of Transfusion Medicine will be featured in exhibits on Dr. Harvey Alter and Dr. Anthony Fauci. Alter, who won the 2020 Nobel Prize in Physiology or Medicine for his discovery of hepatitis C, was also the first to show that asymptomatic AIDS patients can transmit the disease to others through blood transfusions. This discovery informed the creation of the Coulter HIV-1 p24 Antigen Assay, which is part of the technology transfer collection. Alter and the Discovery of Hepatitis C will open in the main corridor of the NIH Clinical Center, across from the FAES bookstore and café, in late spring/early summer 2023.

The Coulter HIV-1 Antigen Assay also cites the work of Dr. Anthony Fauci, HIV/AIDS researcher and NIAID Director from 1984-2022. ONHM is currently developing an exhibit about Dr. Fauci's career, slated to be installed in fall of 2023.

Under Dr. Fauci's leadership, NIAID has coordinated with technology transfer to bring many important vaccines and medications to market, like Synagis. A monoclonal antibody manufactured by MedImmune Inc., Synagis protects infants and children from serious lower respiratory tract diseases resulting from RSV and was approved for use in 1998.



Synagis Vial



BRACAnalysis was manufactured by Myriad using technology from NIEHS.



Coulter HIV-1 p24 Antigen Assay, developed with NIH research.



# Technology Transfer University (TTU) – Spring 2023

Nikki Guyton, NCI

Are you new to technology transfer (T2) and want to learn more about the ins and outs of the field? Or are you a seasoned T2 professional hoping to brush up on certain topics? Maybe you are currently working in another field and considering T2 as an alternative career or your current position interacts with T2 and you'd like more information on certain T2 subjects. In any case, Technology Transfer University (TTU) may be the course that you have been searching for!



Credit: iStock.com/lemono

TTU is a free, one day per week course that runs for seven weeks. TTU covers a variety of topics pertinent to T2, with a view towards T2 at NIH. This year will be our 15th year offering these valuable sessions at NIH. We estimate that throughout the years, approximately 500 NIH, CDC, and FDA staff have enrolled in TTU! Our highest enrollment to date was 2022 with 60 participants.

TTU is taught by NIH's T2 experts. Topics covered include basic principles of intellectual property law, technology transfer-specific laws, technology transfer agreements (including a section on CRADAs), human subject considerations in T2 agreements, patenting processes and licenses, software, contract and grant related issues in T2, T2 marketing, and customer service & negotiation techniques. The full schedule with presenters is provided below. Both in-person and virtual attendance options are available.

It's not too late to register! Please send an email to Nikki Guyton at [guytonn@nih.gov](mailto:guytonn@nih.gov) with your name, email, and which session(s) you will attend, if not all.



Credit: iStock.com/nazarkru

## Technology Transfer University – Spring 2023 Schedule

- AM classes are 9am-12pm and PM classes are 1pm-4pm unless indicated otherwise.
- All classes are scheduled on Wednesdays.
- All classes will be held in NCI Shady Grove Room 01E030 with an option for participation by Zoom (**subject to change based on Montgomery County Covid levels**).

Please view the next page for the complete spring schedule.



## Spring 2023 TTU Schedule

Instructor	Topic	Class Length	Date
Bruce Goldstein	Basic Principles of Intellectual Property Law	Full Day	March 29
Summer Young	Technology Transfer Laws	*10:30am – 12pm	April 5 AM
Lisa Finkelstein & Laurie Whitney	Introduction to Technology Transfer Agreements	1/2 Day	April 5 PM
Michael Pollack	Introduction to CRADAs	1/2 Day	April 12 AM Note: There is no PM session this day
Suzanne Frisbie	Human Subject Use in Technology Transfer Agreements	1/2 Day	April 19 AM
Lisa Finkelstein	Human Subject Use in Technology Transfer – Practical Application	1/2 Day	April 19 PM
Lauren Nguyen-Antczak	Patent Process Part 1	1/2 Day	April 26 AM
Susan Rucker	Patent Process Part 2	1/2 Day	April 26 PM
Sue Ano	Licenses to Patentable Technology	1/2 Day	May 3 AM
Jeff Thomas and Scott Cooper	Software, Contract and Grant Related Issues in Technology Transfer	1/2 Day	May 3 PM
Michael Salgaller	Marketing in Technology Transfer	1/2 Day	May 10 AM
Tom Stackhouse	Customer Service and Negotiation Techniques	*1-3pm	May 10 PM

# “Skate the way the puck is going, not where it’s at” – and Other Lessons from the AUTM Annual Meeting

Anna Solowiej, NHGRI

Another exciting AUTM Annual Conference took place in February 2023 in Austin, Texas. With the attendance of 1,946 registrants (fourth best attendance ever), it was again a great place to reunite with colleagues in person, make new connections, and learn about diverse work topics. This reporter mixed attending plenary and educational sessions with business meetings with universities, companies, and legal providers. Here is a brief summary of keynote sessions as well as highlights of one of the NIH-led panels.

As always, a Fireside Chat (pictured to the right) was the first main event on Sunday evening. AUTM CEO Steve Susalka interviewed Kathi Vidal, Director of the US Patent and Trademark Office, who moved from private legal practice to the federal government because she wanted to make a difference. The Director expressed that she wants to be very engaged with the tech transfer community, hear our ideas, and help us advocate for a stronger patent system. She also discussed many initiatives, such as a first-time filers program for under-resourced inventors, improving 101 guidance in 2023, strengthening PTAB reliability, and having a strong relationship with NIST. Overall, it was a positive and optimistic conversation and outlook.



The Monday Keynote was a motivational talk titled “*Inspiring Change by Embracing Innovation*,” by Marcus Whitney (pictured left), who is a healthcare venture fund founder. He gave four inspirational pieces of advice, with very interesting examples from his life: constraints and problems can lead to clarity and opportunity; cast a dream beyond your comfort; be courageous but classy; and make friends with failure. It was good to hear a talk not directly related to tech transfer, for some perspective and inspiration.

The Tuesday Plenary was a provocative and thoughtful panel discussion about the future of tech transfer “*Reimagining the TTO*” (pictured right). The speakers included tech transfer professionals from five universities, NSF, and one attorney. Many broad themes emerged from the discussion, including the fact that we handle so many activities and services that our job description is not adequate to truly communicate what we do. The quote in the title (from the Canadian philosopher Wayne Gretzky) was also brought up to demonstrate how we should be approaching our work.



The Wednesday Keynote was excellent and nicely connected tech transfer work to real world impact. It was a talk by Maria Elena Bottazzi about “*Development of an Open Access COVID-19 Vaccine.*” Dr. Bottazzi was nominated for the Nobel Peace Prize for this work (with Peter Hotez). She spoke about the decision of her institution and tech transfer team not to pursue an IP for her vaccine work, but instead make it available for free to the world. Her science (recombinant protein technology) is now behind 100 million vaccinations – mainly in India and Indonesia.



Elena Bottazzi (left) and Anna Solowiej (right)

In addition to these keynotes, there were many excellent educational sessions. One very interesting one was led by Dr. Eggerton Campbell from NHGRI and included Steve Ferguson from OTT as one of the panelists. It was a discussion of the “*Art of Negotiating and Monetizing Rare Pediatric Disease Priority Voucher (PRV) Terms.*” Other speakers were from U.S. Army, University of Massachusetts Chan Medical School,

Sarepta Therapeutics, and Salk Institute. The PRV program has been renewed until September 30, 2026 (about 40 vouchers have been issued by the FDA so far), and the panelists were in agreement that PRVs are becoming a regular term in licenses, even though the company representative voiced a dislike for this additional payment that private industry is asked to make.



Steve Ferguson (left) and Eggerton Campbell (right)

And finally, there was a surprise federal tech transfer meetup session – which took place when a session about U.S. manufacturing waivers was cancelled. NIH, NIST, VA, and EPA colleagues shared some of our challenges, and given its strong reception, this might be a regular future event at AUTM!



Downtown Austin on Colorado River

All registered attendees can now access the recorded sessions by logging into [autm.net](https://autm.net), and you can submit your abstracts for the 2024 Meeting in San Diego by April 17!



## iEdison Platform Receives FLC Award

*Richelle Holnick, OTT*

NIH and the National Institute of Standards and Technology (NIST) have won the Interagency Partnership Award for Technology Transfer from the Federal Laboratory Consortium (FLC) for their collaboration on modernizing the iEdison system. iEdison is used to report and categorize inventions and patents that are a result of federally funded research and to document compliance with domestic manufacturing requirements. This collaboration enhanced and modernized the iEdison platform as management of the system was transferred from NIH to NIST.



Credit: iStock.com/PCH-Vector

A working group comprised of half NIH and half NIST staffers was launched in December 2019 to design the platform's IT infrastructure, develop the core user interface, research the requirements of user agencies and non-federal system users, and conduct testing. NIH's Division of Extramural Inventions, its Technology Resources team, and the NIH communications teams were heavily involved in the redesign and transition.

This system allows grantee tech transfer professionals to stay in compliance with Bayh-Dole Act administrative requirements. iEdison also interfaces with federal patent and grants system such as USPTO, SAM.gov, and USASpending.gov to automatically update patent information and organizational data.

The FLC's Interagency Partnership Award for Technology Transfer is awarded to agencies who have collaboratively accomplished outstanding work. iEdison's modernization certainly fits the bill as over 1,000 users logged into the system in the first four days it launched, showing its widespread utility and need. Also, many previously inactive users contacted the help desk with questions about accessing the system and updating records.

Congratulations to everyone involved in this win! If you are interested in submitting an FLC Award nomination, you can find information about the categories and requirements on the [FLC website](#). The submission period runs July-September.





## OSA at AUTM

*Ami Gadhia, Jasmine Kalsi, NCATS*

Ami Gadhia, Senior Technology Transfer and Patenting Specialist at NCATS served on an AUTM Annual Meeting Panel on February 22, 2023 entitled, “When Uncle Sam is Your Co-Inventor”. The discussion was directed towards academic collaborators regarding joint appointments and inventions with the federal government. The panel was moderated by Pattie Cullum, a Regional Technology Transfer (TT) Specialist at the Department of Veterans Affairs (VA). The panelists came from diverse backgrounds such as University of Washington (UW) and the Center for Disease Control (CDC). The topic was joint inventions and began with a discussion about dual appointment personnel (DAP). The idea for the panel was one of the results of Pattie’s FAES Tech Transfer Capstone Project.

This is an important topic since a majority of NCATS inventions are jointly owned. The NCATS engages in team science and hence many of the work is collaborative in nature, most often with universities. In contrast to the DAP mechanism, we at NCATS/NIH negotiate and execute inter-institutional agreements with our joint owners. This is to allow for one party to lead the patenting and licensing of that joint IP. Ami emphasized that the NIH has to use its own IIA template rather than the AUTM Model IIA due to the statutory authorities that govern our work. Further, in addition to the NIH perspective, audience members heard from David Marks, who outlined the rules around DAP arising from joint inventions with the VA; Sam McNeal, currently a CDC Specialist, and formerly a university TT Specialist, outlined his experience with DAP from the university side; and Lisa Norton, currently a UW Licensing Director, also spoke about her university experience with DAP as well as other joint appointments such as with the Howard Hughes Medical Institute and the Fred Hutchison Cancer Center.



## My FLC Experience

*John Bittman, NIST*

The Federal Laboratory Consortium for Technology Transfer (FLC) is a network of over 300 federal laboratories, agencies, and research centers that fosters commercialization, best practice strategies, and opportunities for accelerating federal technologies out of the labs and into the marketplace. It is also an organization run by an Executive Board of federal lab volunteers.

Whether you are looking to expand your technology transfer knowledge, network with technology transfer colleagues from different agencies, or advance your career through volunteer and leadership opportunities, engaging in the FLC can help advance your professional development and bring knowledge and recognition back to your lab.



John Bittman

I was completely unfamiliar with the term “technology transfer” until I came across the NCI Technology Transfer Center while browsing the various offices within NCI as a desperate Presidential Management Fellow trying to secure a detail. The office and mission, operating at the intersection between labs and businesses, sounded like a wheelhouse as my graduate program in nanotechnology was heavily influenced with business development and technology ventures curricula. Luckily, the TTC leadership acquiesced and my journey into the field was off to the races!

Shortly after my first day in technology transfer, more knowledgeable colleagues and experienced team leaders introduced me to the FLC through either the Desk Reference or The Green Book. Those two publications, along with the several white papers and other resources offered, really helped me develop an understanding of the federal technology transfer frameworks, goals, and operations. Today, the FLC continues to educate me through even more means such as the regular webinars and the new on-demand Learning Center.

Beyond education, the FLC has helped expand my network and provide volunteer opportunities that impact the whole field federal technology transfer. In my current role, just knowing the full suite of offerings from the FLC has also helped facilitate the streamlining of some of the technology transfer activities at my new agency, NIST. The FLC contributes in countless more ways to my professional development and has done so since my first day’s learning about technology transfer.



Hopefully this has inspired you to learn more about how to get involved with the FLC. You can find information on the committees [here](#), and information on how to volunteer with the FLC [here](#).

# NIAID Wins USPTO Patents for Humanity Award

*Richelle Holnick, OTT*

The NIH National Institute of Allergy and Infectious Diseases (NIAID) has won the USPTO Patents for Humanity: COVID-19 Award. This award was given to five organizations for their rapid response to the COVID-19 pandemic through the use of technologies.

NIAID, in collaboration with the Scripps Research Institute and Dartmouth College, invented a stabilized coronavirus spike protein that was essential in the development of the COVID-19 vaccines on the market. These spike proteins allow the human immune system to mount effective responses against coronaviruses. This was a crucial step in developing COVID-19 vaccines.

NIAID used nonexclusive licensing to maximize the reach of this invention. By allowing as many vaccine developers as possible to license this technology, NIAID was able to increase the impact of their invention. NIAID also partnered with the World Health Organization through its COVID-19 Technology Access Pool.




NIAID and the other winners were honored at a USPTO awards ceremony in February. You can view the full transcription of USPTO Director Kathi Vidal’s remarks from the award ceremony [here](#).

## Abstract Creation Progress

*Steve Ferguson, OTT*

As reported on in a past edition of the newsletter, the NIH Technology Transfer program has a backlog of over 1,000 technologies that are missing abstracts. Realizing that IC TTOs are busy with a variety of duties and not always able to prepare their abstracts on a timely basis, OTT hired an abstract writer to help fill in the gaps. The abstract writer, Wayne Pereanu, has written 590 abstracts thus far, quite an accomplishment!

We look forward to continuing to work with the ICs to identify and write these “missing” abstracts”. And we can even take “special requests”. If you have a case that would benefit from a new marketing abstract, just let us know and we will move it to the front of the abstract queue!





**NOW SHOWING:**

**ETT TRAINING VIDEOS**

**Featuring new hits: Generate a Competitive Bid  
& Use Query Filters**



**PATENT LEGAL SERVICES  
REMINDER**

**CPARS Annual  
Reviews Due By  
May 5th**

## Comings and Goings



**Brian Bailey** has joined NIAID as a Technology Transfer Patent Specialist for Branch B. Brian holds a Ph.D. in biochemistry from Montana State University (Bozeman, MT), where his dissertation project focused on applying novel methods to solve membrane protein structure problems. He came to NIH in 2001 as a postdoctoral fellow at NIAAA. In 2005, he moved into the field of technology transfer as a Technology Transfer Fellow at NCI, subsequently moving to a permanent position as a Technology Transfer Specialist at NIAID, and since 2008, as a Technology Transfer Manager at NHLBI, where he supported the intramural research programs of NIDCD and NIAMS in addition to NHLBI.



**Veronica Bayne** has joined NIAID as a paralegal. Veronica previously worked at DSM North America in Columbia, MD, and has over 20 years of experience working in IP law firms in Washington, DC.



**Samuel J. Claxton** is a new Product Manager at OTT supporting the ETT project. Previously, Samuel was working on a project at HRSA as a Core Java software developer. He received a Masters of Science in Managing Information Technology (MSMIT), Masters of Business Administration (MBA), and a Bachelor's degree in Information Technology from Sullivan University.



**Nicholas Ratliff** has left his position as a Product Manager at OTT supporting the ETT project. If you were previously working with Nick directly on any reports or forms, please send future requests to [ETT\\_Support@mail.nih.gov](mailto:ETT_Support@mail.nih.gov).



**Logan Richards** has joined NIAID as an ORISE fellow in Technology Transfer and recently completed his Ph.D. in Biological Sciences at Vanderbilt University. While there, he studied the regulation of DNA replication in *Drosophila* and sought professional development outside the bench. In his last year as a graduate student, he served as a Life Sciences Intern at the Center of Technology Transfer and Commercialization at Vanderbilt University. Logan obtained his B.S. in Biochemistry at Purdue University in 2017.



**Abby Rives** has joined the Office of Science Policy as a senior advisor in IMOD to help build NIH's innovation policy portfolio, working closely with Lyric Jorgenson and Mark Rohrbaugh. Abby was most recently IP counsel at a tech entrepreneur startup in DC and prior to that an associate at a global law firm in DC. She graduated from Emory University School of Law and has worked with the CDC and the U.S. Court of Appeals for the Federal Circuit.



**Zehra Sherwani** has joined NCI TTC as a Fellow. Zehra graduated from law school January 2021. She previously worked in a variety of law jobs from Criminal Justice Clinics, Juvenile Justice Courts, and Personal Injury, and she is now looking forward to working here at NCI/NIH. She lives in Michigan and will be working remotely.



**Thanda Wai** has now retired from NIH after more than 19 years of government service. Her federal career included work as Senior Technology License Monitoring & Enforcement Specialist at OTT and also as a Patent Advisor at the US Department of Agriculture. In other IP-related work during her career Thanda served as an IPR Specialist for the International Rice Research Institute in the Philippines and as the Head of the International Patent Depository at American Type Culture Collection. In retirement she is hoping to now travel more and pursue a variety of new hobbies – including sailing. Bon voyage & best wishes, Thanda!



**Jennifer Yu** recently joined OTT as an IT Analyst supporting the ETT project and her primary duties focus on docketing patents and licenses and handling work orders. She also supports the Patent Legal Services team. Before joining OTT, she studied computer science in the College of Engineering at Cornell University. She previously worked as a junior engineer and on a strategy team before moving on to pursue product and data work with OTT.